Rationale for the combination of veliparib with platinum-based chemotherapy.

2556 Background: Owing to the role of PARPs in DNA damage repair, PARP inhibitors (PARPi) are under clinical investigation as anticancer therapies with a focus on tumors with impaired homologous re...